Storage and Custody of Medicines and Biological Samples in Advanced Therapies: Regulations, Methods, and Best Practices
The storage and custody of biological samples and medicines used in advanced therapies (AT), including gene therapy, cell therapy, and tissue engineering, demand a high level of technical and regulatory rigor. Due to their sensitivity, these products require specific storage conditions and strict regulatory compliance to ensure therapeutic efficacy, safety, and traceability.
Regulatory requirements for storing medicines and biological samples in advanced therapies
Logistical requirements in advanced therapies are complex but essential to maintain product quality until the moment of use.
In the European context, Regulation (EC) No. 1394/2007 establishes specific requirements for the classification, manufacture, marketing, and traceability of advanced therapy medicinal products (ATMPs). Other applicable frameworks are the Directive 2004/27/EC on human medicines, which includes provisions for storage, and the EU Guidelines on Good Manufacturing Practices (GMP).
In Spain, Royal Decree 477/2014 regulates non-industrial ATMP manufacturing, while Law 29/2006 outlines general criteria for pharmacovigilance and quality.
These regulations require validated conditions to guarantee the stability and conservation of Advanced Therapy Medicine Products (ATMPs), including continuous monitoring of temperature, humidity, and storage time, as well as record-keeping systems and alarms for incidents.

Key factors for the proper storage of medicines and biological samples
The stability of samples in AT depends on multiple physical and logistical factors:
- Temperature: A strict cold chain is critical, as even minor deviations can compromise the product’s efficacy.
- Relative humidity: Excess humidity can alter compounds or promote microbial growth.
- Light: Many drugs are photosensitive, and improper exposure can degrade active ingredients.
- Packaging: Containers must protect products from external factors and prevent interactions with the content.
- Storage time: Each product has a defined shelf life depending on its storage environment.
- Handling and transport: Must be carried out under controlled conditions to avoid contamination or degradation.

Storage methods: from formaldehyde to ultra-freezing
Various strategies are used to preserve samples and medicines based on their characteristics and clinical application.
- Storing samples in formalin is a traditional method in histological studies due to its ability to preserve cellular structures, though it limits molecular analysis.
- Refrigeration (2–8 °C) is ideal for short-term storage of samples like serum, plasma, or reagents.
- Standard freezing (-20 °C) offers moderate stability but does not ensure cell viability.
- Ultra-low temperature freezing (-80 °C) allows for long-term preservation of nucleic acids and tissues without biomolecular degradation.
- Storage in liquid nitrogen (-196 °C) is essential for preserving live cells through cryopreservation, though there is a risk of damage from ice crystallization.
The choice of method depends on the sample type, intended use, and duration of storage.
Storage and custody: ensuring stability and traceability
The custody of biological samples and medicines requires specialized equipment to guarantee product stability. Storage devices, such as medical refrigerators, ultra-freezers, or cryogenic tanks, must include:
- Real-time temperature monitoring
- Automatic alerts in case of incidents
- Backup power systems
- Remote monitoring capabilities
Biological sample custody also involves logging every step in the logistics chain, from collection to clinical administration. Traceability is ensured through management software and access control systems. These solutions enable a safer and more efficient workflow in compliance with current regulations.
Best practices in the transport of sensitive medicines and biological samples
The transport of biological samples and ATMPs is another critical phase in the preservation chain. Proper execution requires specific protocols and suitable logistical solutions:
- Use of isothermal and cryogenic containers with active thermal control systems
- Continuous temperature monitoring throughout the journey
- Unambiguous identification and traceability via barcodes or smart labels
- Compliance with biosafety and packaging regulations, including triple packaging for infectious samples, leak-proof containers, and absorbent materials in case of breakage
- Full documentation of the custody chain
- Staff training on critical procedures and incident management
These practices are essential in critical contexts where sample and medicine preservation can determine treatment success.

At Bexen Bioservices, we offer specialized solutions to ensure the preservation and traceability of advanced therapies:
- Ultra-low temperature freezing equipment
- Backup power systems
- Remote monitoring systems
- Video surveillance and access control
- Secure and controlled transport systems for samples and medicines
If you’re looking to optimize your processes with safe and reliable solutions, let’s talk.
References
Poveda-Andrés JL, Ruiz-Caldes MJ, Carrera-Soler MJ, Clopés-Estela A, Flores-Moreno S, García-Pellicer J, Giráldez-Quiroga M, López-Briz E, Lozano-Blázquez A, Megías-Vericat JE, Tordera-Baviera M, Valero-García S. Pharmacotherapeutic management of advanced therapy drugs. Farm Hosp. 2022 Jan 27;46(2):88-95. English. PMID: 35379101.
European Commission. Guidelines on Good Manufacturing Practice for Advanced Therapy Medicinal Products [Internet]. Brussels: European Commission; 2017 [cited 30 abril 2025. Available from: https://health.ec.europa.eu/document/download/e1786e5d-1587-42af-b8ff-6a810ccb6836_en?filename=pharm731_2ib_atmps_guidelines.pdf
European Union, Eur-Lex (Luxembourg). Reglamento (CE) nº 1394/2007 del Parlamento Europeo y del Consejo, de 13 de noviembre de 2007, sobre medicamentos de terapia avanzada y por el que se modifican la Directiva 2001/83/CE y el Reglamento (CE) nº 726/2004 [Internet]. Luxembourg: Publications Office of the European Union; 2007 [cited April 30, 2025]. Available from: https://www.boe.es/buscar/doc.php?id=DOUE-L-2007-82262
European Union, Eur-Lex (Luxembourg). Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004 [Internet]. Luxembourg: Publications Office of the European Union; 2007 [cited April 30, 2025]. Available from: https://eur-lex.europa.eu/legal-content/ES/ALL/?uri=CELEX:32004L0027
Agencia Española de Medicamentos y Productos Sanitarios. Guía de Normas de Correcta Fabricación de Medicamentos de Uso Humano y Veterinario. [Internet]. Madrid: AEMPS; 2011 [cited April 30, 2025]. Available from: https://www.aemps.gob.es/industria/inspeccionNCF/guiaNCF/docs/reqBasicosMed/07_capitulo-4b.pdf
Agencia Estatal Boletín Oficial del Estado (España). Real Decreto 477/2014, de 13 de junio, por el que se regula la autorización de medicamentos de terapia avanzada de fabricación no industrial [Internet]. Madrid: Ministerio de Sanidad; 2014. [cited April 30, 2025]. Available from: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2014-6277 Agencia Estatal Boletín Oficial del Estado (España). Ley 29/2006, de 26 de julio, de garantías y uso racional de los medicamentos y productos sanitarios [Internet]. Madrid: Ministerio de Sanidad; 2006 [cited April 30, 2025]. Available from: https://www.boe.es/buscar/act.php?id=BOE-A-2006-13554